glp-1 agonists market Receptor Agonist Report: Size, Growth, Trends & Forecast (2025–2033) Glucagon-Like Peptide 1 (GLP-1) Agonist

Cycle Length: Short cycles of 4 to 6 weeks are common to avoid receptor desensitization and long-term side effects

Cycle Duration and Monitoring Typical cycle: 1224 weeks Monitoring: baseline and 1012 week IGF-1 measurement is the most common biomarker Washout: 48 weeks between cycles is standard practitioner practice Contraindications Active malignancy GH/IGF-1 axis elevation is a theoretical oncogenic concern Diabetes mellitus GH elevates insulin resistance

This angiogenic effect appears to work through the upregulation of vascular endothelial growth factor (VEGF) and other growth factors critical for tissue repair

Iyer KS, Marks GA, Kastin AJ, McCann SM

We are confident you will too